Security
BioHarvest Sciences Inc. Common Stock · BHST
BHSTNASDAQCommon stockCurrentCIK 1723464Updated Oct 14, 2026
Name history
CANNA-V-CELL SCIENCES INC. · through Apr 21, 2020Midnight Star Ventures Corp. · through Oct 15, 2018
BHST price & chart
Loading TradingView…
NASDAQ:BHST on TradingView ↗About the company
BioHarvest Sciences Inc. (Nasdaq: BHST) (TASE: BHST) (FSE: 8MV0) is a biotechnology company pioneering its proprietary Botanical Synthesis™ technology, an advanced plant-cell-based platform designed to produce valuable plant-derived compounds without growing and harvesting the complete source plant. The Company applies Botanical Synthesis™ across its proprietary asset portfolio and through its CDMO business to develop and manufacture high-value plant-derived compounds for customers and commercial partners. VINIA® represents BioHarvest’s first commercialized product and provides a demonstrated pathway from plant-cell development through manufacturing and commercialization. BioHarvest is applying that same platform to build a broader portfolio of proprietary and customer-sponsored assets across multiple high-value categories.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| Total AssetsUSD | 47,665,000Source | 25,001,000Source | 15,002,000Source |
| Property, Plant and Equipment, NetUSD | 8,326,000Source | 7,750,000Source | 3,926,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 23,025,000Source | 2,390,000Source | 5,355,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,981,000Source | 1,116,000Source | 808,000Source |
| Inventory, NetUSD | 4,559,000Source | 3,655,000Source | 2,466,000Source |
| Assets, CurrentUSD | 30,500,000Source | 7,856,000Source | 9,052,000Source |
| Operating Lease, Right-of-Use AssetUSD | 8,406,000Source | 9,024,000Source | 1,845,000Source |
| LIABILITIES AND EQUITY | |||
| Stockholders’ equity: | |||
| Additional Paid in CapitalUSD | 133,001,000Source | 97,748,000Source | 68,652,000Source |
| Retained Earnings (Accumulated Deficit)USD | -107,553,000Source | -96,418,000Source | -83,505,000Source |
| Stockholders' Equity Attributable to ParentUSD | 25,448,000Source | 1,330,000Source | -14,853,000Source |
| Liabilities and EquityUSD | 47,665,000Source | 25,001,000Source | 15,002,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 7,684,000Source | 14,258,000Source | 26,467,000Source |
| Accounts Payable, CurrentUSD | 2,627,000Source | 3,525,000Source | 1,778,000Source |
| Other Liabilities, NoncurrentUSD | 1,983,000Source | 272,000Source | 1,963,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 386,000Source | 401,000Source | 458,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Profit or LossUSD | -11,135,000Source | -12,913,000Source | -12,564,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 1,624,000Source | 1,251,000Source | 840,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | 865,000Source | 308,000Source | 262,000Source |
| Increase (Decrease) in InventoriesUSD | 904,000Source | 1,189,000Source | 1,088,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -7,226,000Source | -6,684,000Source | -8,522,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,365,000Source | -3,027,000Source | -1,474,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,355,000Source | 2,835,000Source | 1,474,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 30,187,000Source | 6,780,000Source | 13,556,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 20,596,000Source | -2,931,000Source | 3,560,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 23,025,000Source | 2,390,000Source | 5,355,000Source |
| Supplemental disclosure of cash flow information: | |||
| Income Taxes Paid, NetUSD | 39,000Source | — | — |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | — | 601,000Source | 563,000Source |
| GeneralAndAdministrativeExpenseUSD | 4,927,000Source | 4,401,000Source | 4,482,000Source |
| Income Tax Expense (Benefit)USD | -76,000Source | 8,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -11,135,000Source | -12,913,000Source | -12,564,000Source |
| Operating ExpensesUSD | 26,051,000Source | 20,931,000Source | 15,599,000Source |
| Proceeds from Issuance of Common StockUSD | 18,262,000Source | 4,330,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | 36,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 34,508,000Source | 25,188,000Source | 12,672,000Source |
| Cost of Goods and Services Sold | — | — | — |
| Operating Income (Loss)USD | -5,575,000Source | -6,989,000Source | -9,966,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -11,059,000Source | -12,905,000Source | -12,564,000Source |
| Income Tax Expense (Benefit)USD | -76,000Source | 8,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -11,135,000Source | -12,913,000Source | -12,564,000Source |
| Earnings Per Share, BasicUSD per share | -0.6Source | -0.8Source | -0.93Source |
| Additional Financial Items | |||
| GeneralAndAdministrativeExpenseUSD | 4,927,000Source | 4,401,000Source | 4,482,000Source |
| GrossProfitUSD | 20,476,000Source | 13,942,000Source | 5,633,000Source |
| Operating ExpensesUSD | 26,051,000Source | 20,931,000Source | 15,599,000Source |
| ResearchAndDevelopmentExpenseUSD | 5,312,000Source | 4,797,000Source | 3,369,000Source |
| SellingExpenseUSD | 15,812,000Source | 11,733,000Source | 7,748,000Source |
Filing attachments
bhsc_ex991.htm · 6-K · 2026-10-13
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest’s GMP facility Milestone demonstrates BioHarvest’s ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercializat…
Read attachment ↗bhsc_ex991.htm · 6-K · 2026-10-08
TATE & LYLE AND BIOHARVEST REACH KEY MILESTONE IN NEXT-GENERATION SWEETENER DEVELOPMENT PROGRAMME Progress demonstrates that BioHarvest’s Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution Vancouver, British Columbia and Rehovot, Israel - October 8, 2026 - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announc…
Read attachment ↗bhsc_ex991.htm · 6-K · 2026-10-02
BioHarvest Sciences Announces Share Repurchase Program Vancouver British Columbia and Rehovot, Israel - September 29, 2026 - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in accordance with Canadian practic…
Read attachment ↗bhsc_ex991.htm · 6-K · 2026-09-15
FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Street Vancouver, BC, V6C 2T6 (the “Company” or “BioHarvest”) Item 2. Date of Material Change September 8, 2026 Item 3. News Release The news release (the “News Release”) was issued on September 3, 2026 and disseminated by Newsfile Corp. Item 4. Summary of Material Change The Company announced its intention to register its common shares without par value (the “Commo…
Read attachment ↗bhsc_ex991.htm · 6-K · 2026-09-15
BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product Single-dose VINIA Daily Chews broaden demographics and usage occasions while demonstrating the commercial versatility of Botanical Synthesis Format expansion shows how BioHarvest can help CDMO partners move from plant-cell compositions to differentiated consumer products Vancouver, British Columbia and Rehovot, Israel - September 15, 2026 - BioHarvest Sciences Inc. (Nasdaq…
Read attachment ↗bhsc_ex991.htm · 6-K · 2026-09-14
BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (Nasdaq: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held Septem…
Read attachment ↗